CVRx, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
CVRx announced August 11, 2026, that Chief Revenue Officer Robert John is departing immediately. Paul Verrastro, an internal senior advisor with 30+ years of medical device experience and 5+ years at CVRx (former Chief Marketing and Strategy Officer), assumes interim Head of Sales role while the company searches for a permanent successor. CEO Kevin Hykes cited 'revised commercial outlook and need to improve commercial execution' as the reason for the change.
Why this rating
Leadership departure in commercial/sales function is material given company's commercial-stage status and small $112M market cap. Interim replacement is internal, mitigating risk. But 'revised commercial outlook' signals guidance pressure.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.